Category - Developments

Developments

Titan Pharma’s Probuphine added to Federal Supply Schedule

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant, a novel six-month maintenance treatment for opioid use disorder (OUD), will be included on the Federal Supply Schedule (FSS) beginning on January 15, 2020. The...

January 13, 2020

Developments

Profound Medical inks its first U.S. multicenter agreement for TULSA-PRO; provides commercialization update

Profound Medical (NASDAQ:PROF; TSX:PRN) signed its first U.S. multi-site imaging center agreement for TULSA-PRO with RadNet (NASDAQ:RDNT), a leading provider of fixed-site outpatient diagnostic imaging services with a...

January 10, 2020

Developments

Law firms Troutman Sanders and Pepper Hamilton to merge

Troutman Sanders and Pepper Hamilton agreed to merge, effective on April 1, creating a new 1,100-lawyer giant with offices in 23 locations, including eight of the 10 top U.S. markets. The new firm will be known as...

January 10, 2020

Developments

BriaCell identifies new breast cancer responders based on cancer grade

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXD) identified a new group of patients with high levels of clinical benefit in response to its immunotherapy, and in combination with checkpoint inhibitors. After a reanalysis...

January 9, 2020

Developments

IntelGenx enters animal health market with VetaFilm feasibility agreement

IntelGenx (TSXV:IGX; OTCQX:IGXT) entered into a feasibility study agreement with an undisclosed partner focused on bringing innovative animal health products to the market. IntelGenx will conduct a feasibility study on...

January 9, 2020

Developments

Hepion to present update on CRV431 nonclinical studies at NASH-TAG 2020 conference

Hepion Pharmaceuticals (NASDAQ:HEPA) is slated to present a poster at the upcoming NASH-TAG 2020 conference. The presentation will provide details of four nonclinical studies demonstrating that CRV431 decreases liver...

January 8, 2020

Developments

Imagin Medical successfully completes i/Blue’s design verification

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) completed design verification of its i/Blue Imaging System functional unit on schedule. i/Blue is based on advanced optics and light sensors...

January 8, 2020

Developments

Apellis reports positive topline Phase 3 data in paroxysmal nocturnal hemoglobinuria

Apellis Pharmaceuticals (NASDAQ:APLS) reported positive topline results from its Phase 3 study evaluating pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Pegcetacoplan met the study’s...

January 7, 2020

Developments

Hepion paper published in Expert Opinion on Investigational Drugs

Hepion Pharmaceuticals’ (NASDAQ:HEPA) comprehensive review of studies on the role of cyclophilins in non-alcoholic steatohepatitis (NASH) and NASH-related liver disease has been published in peer-reviewed journal...

January 6, 2020

Developments

iBio initiates new litigation against Fraunhofer

iBio (NYSE AMERICAN:IBIO) filed a motion in the Court of Chancery of the State of Delaware to initiate new litigation against Fraunhofer-Gesellschaft through an amended complaint. The new motion asserts that depositions...

January 6, 2020

Category - Developments

Titan Pharma’s Probuphine added to Federal Supply Schedule

Profound Medical inks its first U.S. multicenter agreement for TULSA-PRO; provides commercialization update

Law firms Troutman Sanders and Pepper Hamilton to merge

BriaCell identifies new breast cancer responders based on cancer grade

IntelGenx enters animal health market with VetaFilm feasibility agreement

Hepion to present update on CRV431 nonclinical studies at NASH-TAG 2020 conference

Imagin Medical successfully completes i/Blue’s design verification

Apellis reports positive topline Phase 3 data in paroxysmal nocturnal hemoglobinuria

Hepion paper published in Expert Opinion on Investigational Drugs

iBio initiates new litigation against Fraunhofer

Follow Us

General

More

Subscribe